Montreal Clinical Research Institute, 110, avenue des Pins Ouest, Montreal, QC, H2W 1R7, Canada; Department of Biomedical Sciences, Faculty of Medicine, Université de Montréal, 2900, Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.
Montreal Clinical Research Institute, 110, avenue des Pins Ouest, Montreal, QC, H2W 1R7, Canada; Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, 7101 Av du Parc, Montréal, QC, H3N 1X9, Canada.
Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):658-665. doi: 10.1016/j.numecd.2020.10.006. Epub 2020 Oct 17.
The first hybrid artificial pancreas (AP) systems with insulin only (mono-hormonal) have recently reached the market while next generations systems are under development including those with glucagon addition (bi-hormonal). Understanding the expectations and impressions of future potential users about AP systems is important for optimal use of this clinically effective emerging technology.
An online survey about AP systems which consisted of 50 questions was addressed to people with type 1 diabetes in the province of Quebec, Canada. Surveys were completed by 123 respondents with type 1 diabetes (54% women, mean (SD) age 40.2 (14.4) y.o., diabetes duration 23.7 (14.1) years, 58% insulin pump users and 43% glucose sensor users). Of the respondents, 91% understood how AP systems work, 79% trusted them with correct insulin dosing, 73% were willing to replace their current treatment with AP and 80% expected improvement in quality of life. Anxiety about letting an algorithm control their glucose levels was expressed by 18% while the option of ignoring or modifying AP instructions was favoured by 88%. As for bi-hormonal AP systems, 83% of respondents thought they would be useful to further reduce hypoglycemic risks.
Overall, respondents expressed positive views about AP systems use and high expectations for a better quality of life, glycemic control and hypoglycemia reduction. Data from this survey could be useful to health care professionals and developers of AP systems.
首款仅含胰岛素的混合式人工胰腺(AP)系统(单激素系统)最近已推向市场,而包括添加胰高血糖素的下一代系统(双激素系统)也正在研发中。了解未来潜在使用者对 AP 系统的期望和印象,对于优化这种具有临床疗效的新兴技术的使用至关重要。
我们向加拿大魁北克省的 1 型糖尿病患者在线发送了一份关于 AP 系统的调查问卷,共包含 50 个问题。共有 123 名 1 型糖尿病患者完成了问卷(54%为女性,平均(标准差)年龄 40.2(14.4)岁,糖尿病病程 23.7(14.1)年,58%为胰岛素泵使用者,43%为血糖传感器使用者)。在这些受访者中,91%的人了解 AP 系统的工作原理,79%的人信任它能正确给予胰岛素剂量,73%的人愿意用 AP 系统替代他们目前的治疗方案,80%的人期望生活质量能得到改善。18%的人对让算法控制血糖水平表示担忧,而 88%的人则更倾向于选择忽略或修改 AP 系统的指令。至于双激素 AP 系统,83%的受访者认为它们将有助于进一步降低低血糖风险。
总体而言,受访者对 AP 系统的使用表示出积极的看法,并对改善生活质量、血糖控制和降低低血糖风险抱有很高的期望。本调查的数据可能对医疗保健专业人员和 AP 系统的开发者有用。